Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEROnA: Vandetanib-eluting beads in liver malignancies
NCT03291379Phase 1Completed
- Sponsor
- Boston Scientific Corporation
- Start
- May 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vandetanib in hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC), sponsored by Boston Scientific Corporation. Primary endpoints: Safety and Tolerability of Treatment With BTG-002814 at 9 weeks, Maximum Concentration of Vandetanib and N-desmethyl Vandetanib in Plasma and 3 more. Started May 2017; status: completed.
02
Drugs
vandetanib
03
Conditions
hepatocellular carcinoma (HCC)metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03291379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03291379.